Drug major Sun Pharmaceutical Industries Tuesday reported a consolidated net loss of Rs 218.82 crore for the July-September quarter on account of a Rs 1,214-crore provision for the settlement of the Modafinil antitrust case in the US.
The company had posted a net profit of Rs 912.12 crore for the corresponding period of the previous fiscal, Sun Pharmaceutical Industries said in a BSE filing.
After accounting for the provision of Rs 1,214 crore for the estimated settlement amount payable to all the remaining plaintiffs related to the Modafinil antitrust litigation in the US, the net loss for the quarter was at Rs 219 crore, it said.
The company had entered into a settlement with some complainants in the antitrust case last year.
Adjusted net profit for the second quarter of FY19 was at Rs 996 crore with resulting adjusted net profit margin at 14.5 per cent, Sun Pharma said.
Consolidated revenue from operations of the company stood at Rs 6,846.48 crore for the quarter under consideration. It was Rs 6,590.06 crore for the same period a year ago.
On the results, Sun Pharma MD Dilip Shanghvi said: "Our soft Q2 performance is not a reflection of the underlying health of the overall business. We continue to focus on strengthening our core operations and enhancing our overall efficiencies. We are fairly positive on our performance for the rest of the year. We are excited about the successful launch of Ilumya in the US."
Sale of branded formulations in India for the second quarter of FY19 was at Rs 1,860 crore, down by 16 per cent mainly due to a planned one-time inventory reduction in the supply chain coupled with a higher base of the second quarter last year, Sun Pharma said.
Sales in the US were at USD 342 million (around Rs 2,484 crore) for the quarter, a growth of 11 per cent over same period last year and accounting for 35 per cent of the total sales for the quarter, it added.
The company's sales in emerging markets were at USD 195 million (around 1,416 crores) for the quarter under consideration, flat over the same quarter last year, Sun Pharma said.
Formulation sales in Rest of World (ROW) markets excluding US and emerging markets were at USD 108 million (around Rs 784 crore) in the second quarter of FY19, a de-growth of 2 per cent from the same quarter last year, it added.
"Our API business imparts benefits of vertical integration for our formulations business. We continue to increase the API supply for captive consumption for key products. For Q2 FY19, external sales of API were at Rs 426 crore, up by 10 per cent over Q2 last year," Sun Pharma said.
Consolidated research and development expense for the second quarter of the current fiscal was Rs 452 crore, 6.6 per cent of sales compared to Rs 511 crore (7.7 per cent) of sales for the second quarter of the last year, it added.
Shares of Sun Pharmaceutical Industries today closed at Rs 561.70 on BSE, down 4.72 per cent from their previous close.
(With inputs from agencies.)